OncLive TV

Syed Abbas Ali, MBBS, discusses the identification of novel targets for patients with multiple myeloma who previously progressed on BCMA-targeted agents.

Farrukh Awan, MD, delves into CAR T-cell therapy and its impact on the chronic lymphocytic leukemia treatment paradigm.

Jatinder Lamba, PhD, MSc, discusses the potential clinical application of rapid long-read sequencing for the diagnosis of acute myeloid leukemia.

Alberto Montero, MD, MBA, CPHQ, discusses data with the combination of zanidatamab and evorpacept in HER2-positive and HER2-low metastatic breast cancer.

Stephanie L. Graff, MD, FACP, FASCO, discusses current strategies for fertility preservation in patients with breast cancer.

Stephanie L. Graff, MD, FACP, FASCO, discusses data supporting the use of GnRH agonists for premenopausal women with breast cancer undergoing chemotherapy.

Marco Ruella, MD, discusses strategies to improve access to CAR T-cell therapy for the management of multiple myeloma in minority health populations.

Marcel van den Brink, MD, PhD, discusses a high-fiber dietary intervention for early-stage plasma cell disorders designed for multiple myeloma

Benjamin P. Levy, MD, shares insight on current challenges with TROP2-directed antibody-drug conjugates in NSCLC.

Marco Ruella, MD, discusses disparities in access to commercial anti-BCMA CAR T-cell therapy among minority populations (MHPs) with multiple myeloma.

Chandler Park, MD, FACP, discusses patient characteristics, disease factors, and drug mechanisms of action that influence treatment decisions in mHSPC.

Paolo Ghia, MD, PhD, discusses OS outcomes with first-line ibrutinib plus venetoclax in patients with CLL vs an age-matched general European population.

Zosia Piotrowska, MD, MHS, discusses the importance of differentiating between HER2 alterations among patients with non–small cell lung cancer.

John H. Strickler, MD, details the rationale for evaluating telisotuzumab adizutecan in advanced gastric/GEJ cancer.

Nicolas Girard, MD, discusses differences in the mechanisms of action for HER2-directed TKIs vs antibody-drug conjugates in HER2-mutant NSCLC.

Pedro Barata, MD, discusses electing appropriate testing methods in patients with mCRPC.

Alan Tan, MD, discusses the IO-based combination therapies that are available for the treatment of patients with RCC.

Zosia Piotrowska, MD, MHS, discusses disease factors that guide treatment decision-making and sequencing for patients with HER2-mutated NSCLC.

Bartosz Chmielowski, MD, PhD, discusses the rationale for investigating oncolytic viruses in melanoma.

Raza Hoda, MD, FASCP, discusses characterizing hormone receptor–positive, HER2-low, -ultralow, and -null breast carcinoma in the metastatic setting.

Armin Ghobadi, MD, discusses the efficacy and safety of WU-CART-007 in heavily pretreated patients with relapsed/refractory T-ALL and LBL.

Timothy S. Fenske, MD, MS, discusses implications for data on the omission of auto-HCT in MCL after first CR and with undetectable MRD.

Yair Lotan, MD, discusses the benefits and complications associated with radical cystectomy for patients with BCG-unresponsive NMIBC.

Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.

Craig Eckfeldt, MD, PhD, discusses the current treatment paradigm in MDS and the unmet needs in different subsets of patients.

Whitney Goldsberry, MD, discusses considerations for selecting a PARP inhibitor in the maintenance treatment of ovarian cancer.

Jonathan Wesley Riess, MD, MS, discusses data from the phase 3 HARMONi-2 trial evaluating ivonescimab vs pembrolizumab in advanced NSCLC.

Yair Lotan, MD, discusses the evolving treatment paradigm for Bacillus Calmette-Guérin–unresponsive non–muscle-invasive bladder cancer.

Laura A. Huppert, MD, discusses survival outcomes of patients with metastatic breast cancer and leptomeningeal disease according to disease subtype.

Polly Niravath, MD, discusses a chemotherapy-free regimen of durvalumab, trastuzumab, and pertuzumab in HER2-enriched early breast cancer.